Correction to: Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate

Prostate Cancer Prostatic Dis. 2022 Apr;25(4):800-801. doi: 10.1038/s41391-021-00401-9.

Authors

Scott T Tagawa¹, Krishnan Ramaswamy², Ahong Huang³, Jack Mardekian⁴, Neil M Schultz⁵, Li Wang³, Rickard Sandin⁶, Stanislav Lechpammer⁷, Daniel J George⁸

Affiliations

¹ Weill Cornell Medicine, New York, NY, USA.
² Pfizer Inc., New York, NY, USA. krishnan.ramaswamy@pfizer.com.
³ STATinMED Research, Plano, TX, USA.
⁴ Pfizer Inc., New York, NY, USA.
⁵ Astellas Pharma Inc., Northbrook, IL, USA.
⁶ Pfizer AB., Sollentuna, Sweden.
⁷ Pfizer Inc., San Francisco, CA, USA.
⁸ Duke Cancer Institute, Duke University School of Medicine, Durham, NC, USA.

No abstract available

Publication types

Published Erratum